Corvus Pharmaceuticals, Inc. (CRVS)
2025-06-30 | ||||
|---|---|---|---|---|
| Cumulative foreign currency translation adjustment | 125 | |||
| Unrealized loss on marketable securities | -19 | |||
| Income (loss) from equity method investment | -389 | |||
| Research and development | 7,873 | |||
| General and administrative | 2,387 | |||
| Total operating expenses | 10,260 | |||
| Loss from operations | -10,260 | |||
| Interest income and other expense, net | 639 | |||
| Change in fair value of warrant liability | -2,012 | |||
| Income (loss) before equity method investment | -7,609 | |||
| Net income (loss) | -7,998 | |||
| Comprehensive income (loss) | -7,892 | |||
| Earnings per share, basic | -0.1 | |||
| Earnings per share, diluted | -0.1 | |||
| Weighted average number of shares outstanding, basic | 77,774,344 | |||
| Weighted average number of shares outstanding, diluted | 77,774,344 | |||